Nibinase Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Sunitinib

Indications/Uses

Unresectable &/or metastatic malignant GI stromal tumor (GIST) after failure of imatinib mesylate due to resistance or intolerance. Advanced &/or metastatic renal cell carcinoma (MRCC). Unresectable or metastatic well-differentiated pancreatic neuroendocrine tumors (pNET) w/ disease progression.

Dosage/Direction for Use

GIST & MRCC 50 mg once daily for 4 consecutive wk followed by 2-wk off period (sched 4/2) to comprise a complete cycle of 6 wk. pNET 37.5 mg once daily w/o scheduled rest period.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01EX01 - sunitinib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Nibinase cap 12.5 mg

Packing/Price

1's

Form

Nibinase cap 25 mg

Packing/Price

1's

Form

Nibinase cap 50 mg

Packing/Price

1's

Nibinase

sunitinib

Manufacturer:

Sun Pharma